Skip to Content

Tag: weight loss drugs

Also Noted

LifeMD, Withings partner on weight management

May 2, 2024HME News Staff

NEW YORK and BOSTON – A new strategic partnership designed to advance weight management care will see LifeMD provide its GLP-1 weight-loss patients with advanced in-home health monitoring devices from Withings Health Solutions, including the Body pro 2 scale and the BPM Connect Pro blood pressure monitor. Through the partnership, LifeMD, a provider of virtual primary care services, provides clinicians with near real-time and actionable patient data that can drive compliance, enhance clinical...

LifeMD, weight loss drugs, Withings Health

Read Full Articlered right arrow icon

Also Noted

New weight loss drug reduces AHI in certain patients

April 17, 2024HME News Staff

INDIANAPOLIS – Eli Lilly and Company’s tirzepatide injection diabetes and weight loss drug may help reduce AHI in patients with sleep apnea, according to the results of the company’s phase 3 clinical trials. The Surmount-OSA Study 1 evaluated tirzepatide in adults with moderate-to-severe OSA and obesity who were not on PAP therapy for 52 weeks. Tirzepatide led to a mean AHI reduction from baseline of 27.4 events per hour compared to a mean AHI reduction from baseline of 4.8 events...

Sleep Apnea, Tirzepatide, weight loss drugs

Read Full Articlered right arrow icon

Also Noted

Indie pharmacies report shortages 

February 15, 2024HME News Staff

ALEXANDRIA, Va. – Nearly 96% of independent pharmacy owners and managers report experiencing shortages or backorders of GLP-1 drugs, according to the results of a new survey from the National Community Pharmacists Association. Most report ordering the drugs upon paid claims (63%) rather than keeping a stock on hand (37%) due to high prices and low reimbursement from pharmacy benefit managers, the survey found. “GLP-1s have been tremendously popular over the last couple of years...

National Community Pharmacists Association (NCPA), weight loss drugs

Read Full Articlered right arrow icon

Mick Farrell


ResMed starts tracking patients on both weight loss drugs, CPAP therapy

January 5, 2024Liz Beaulieu, Editor

YARMOUTH, Maine – ResMed CEO Mick Farrell believes that, based on the company’s early research, weight loss drugs will be a “net positive” for patient flow for sleep apnea.  “I mean, I think there's $1 trillion worth of market cap now from these (pharmaceutical) companies and they will turn that into marketing to bring people in for the miracle drug,” he said during a recent conference call to discuss ResMed’s latest financial results. “And...

CPAP, CPAP Device, Mick Farrell, ResMed, weight loss drugs

Read Full Articlered right arrow icon



Industry weighs potential impact of weight loss drugs

November 17, 2023Theresa Flaherty, Managing Editor

YARMOUTH, Maine – Respondents to a recent HME Newspoll aren’t quite sure what to make of the weight loss drug craze and whether or not it will impact demand for certain HME.  Nearly 40% of respondents say the drugs, which are known as GLP-1s and which include brand names like Ozempic and Wegovy, could reduce demand for CPAP devices, as obesity is among the most important risk factors for sleep apnea.  “Over time, I think this will have a huge impact on PAP devices...

Diabetes, Sleep Apnea, weight loss drugs

Read Full Articlered right arrow icon